Glycoprotein Ib-IX-V complex – von Willebrand factor (GPIb-IX-V – vWF) (GPIb-IX-V – vWF)

The Glycoprotein Ib-IX-V (GPIb-IX-V) complex is a vital platelet-specific adhesion receptor composed of four transmembrane subunits: GPIbα, GPIbβ, GPIX, and GPV [1, 4]. Its primary biological role is to mediate the initial tethering and rolling of platelets on the blood vessel wall by binding to the A1 domain of von Willebrand factor (vWF), especially under high-shear conditions found in arteries [2, 5]. This interaction is essential for normal hemostasis, as it allows platelets to adhere to damaged subendothelium and initiate the formation of a platelet plug [3, 4]. However, overactivity or inappropriate activation of this axis is a major driver of arterial thrombosis, contributing to myocardial infarction, ischemic stroke, and thrombotic thrombocytopenic purpura (TTP) [5, 6]. Pharmacological targeting of the GPIb-IX-V – vWF interaction, such as with the nanobody caplacizumab, has proven effective in preventing microvascular thrombosis by blocking vWF-mediated platelet recruitment [6]. Because this interaction is specifically required for high-shear thrombosis, it represents an attractive therapeutic target for developing antithrombotic drugs that may carry a lower risk of systemic bleeding complications than conventional antiplatelet therapies [4, 5].

Other names

CD42 complexGPIb-V-IXvWF-GPIb axisPlatelet glycoprotein Ib complexvWF-GPIbα interaction

Inhibition of the interaction between the platelet Glycoprotein Ib-IX-V receptor complex and the A1 domain of von Willebrand factor to prevent shear-induced platelet adhesion and aggregation [5, 6].